Niagen Bioscience (NAGE) Free Cash Flow (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Free Cash Flow data on file, last reported at -$1.2 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 115.15% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was $4.4 million, a 77.52% decrease from a year earlier, with the FY2025 full-year figure at $13.5 million, up 11.52% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$1.2 million, down from $704000.0 in the prior quarter.
• Over the last five years, Free Cash Flow for NAGE reached as high as $8.6 million in Q4 2024 and fell as low as -$7.2 million in Q1 2022.
• Historically, Free Cash Flow has averaged $966941.2 across 5 years, with a median of $649000.0 in 2023.
• Across the five-year window, Free Cash Flow soared 2572.2% in 2025 and plunged 115.15% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$328000.0 in 2022, then soared by 297.87% to $649000.0 in 2023, then soared by 1222.5% to $8.6 million in 2024, then sank by 91.8% to $704000.0 in 2025, then sank by 269.6% to -$1.2 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$1.2 million in Q1 2026, $704000.0 in Q4 2025, and $3.7 million in Q3 2025.